HEALTH OF WOMAN. 2016.9(115):123–128; doi 10.15574/HW.2016.115.123 
 

Immunomodulatory features of modern probiotic preparations in complex treatment of women of reproductive age with chlamydial infection in the lower genital

Benyuk V. A., Kurchenko A. I., Shcherba О. A., Weiwei Bu

A.A. Bogomolets National Medical University, Kiev

The aim of the study: assessment of influence of complex treatment of chronic recurrent chlamydial cervical infection with probiotics of various forms of the use on the immune status and the vaginal microbiocenosis in women of reproductive age.

Materials and methods. The study surveyed 87 women of age from 18 to 35 years, from which 67 patients of recurrent chlamydial cervicitis, which (according to the protocol) were eligible for inclusion. The control group included 20 gynecologicaly healthy women. All surveyed women were representative by age and data of the obstetric-gynecologic and somatic anamnesis.

In accordance with the objectives of the study, all patients with chlamydia infection (CHI) before the appointment of therapy were randomized into two groups matched for age, symptoms and duration of the inflammatory process. The I (main) group included 35 patients who underwent complex therapy. Part of therapy included drugs Sumamed 250 mg (1 capsule) 1 time a day for 5-7 days according to the scheme: 1st day – 1 g (4 capsules) with the 2nd -3rd day – 500 mg per day (2 capsules) and 4th – 7th day – 250 mg per day (1 capsule). Topically applied combination of reparative, anti-inflammatory and antimicrobial drug Depantol in the form of suppositories – appointed standard one vaginal suppository twice a day for 10 days. Later was appointed eubiotic Lacto® 2 capsules 3 times a day during 3 weeks. The II group included 32 patients (comparison group) who underwent treatment involving Sumamed and Depantol, but with the subsequent appointment of local eubiotiks (1 vaginal suppository at night) – 10 days.

Results. The results of the survey of women of reproductive age with chronic recurrent chlamydial cervicitis during colposcopic study found a high frequency of cervical pathologies, namely, inflammatory changes – 100%, ectopia prismatic epithelium – 32.8%, the true erosion – 19.4%, that in 5.9% cases was combined with leukoplakia, and dysplasia – 16.4%, which correlated with cytological examination (ASCUS – 68.6%, LSIL – 25.5%, HSIL and 2.9%).

Most women with CHI noted deep violations of microbiocenosis of the vagina with a predominance of opportunistic pathogenic bacteria: Peptostreptococcus – in 43.3%, Corynebacterium – in 56.7%, epidermal staph in 65.7% and gardnerellas – in 74.6%, candida – in 46.3% of cases.

Patients with CHI were stated a lack of interferon Genesis – reduction of IFN-a 1.4-fold and IFN-g – 1.8 times.

Conclusion. The complex therapy of chronic recurrent chlamydial cervicitis in women of reproductive age was conducted by the developed algorithm with the inclusion of oral probiotic Lacto® contributed to the increase of parameters of nonspecific resistance of the organism in 88% of cases, which was reflected in the reduction of titers of specific IgM 1.4-fold, IgG – 1.8 times, raising the level of lysozyme in cervical mucus – 1.5 times and sIgA – 1.2 times, the restoration of cytokine profile and normalization of microbiocenosis of the vagina in 76.4% of women.

Key words: probiotics, immunity, cytokines, T-lymphocytes, microbiocenosis, Saccharomyces, Bifidobacterium, antibiotic-associated diarrhea, chlamydial infection, efficiency.

REFERENCES

1. Beniuk VO, Kurcheko AI, Honcharenko VM. 2014. Kliniko-imunolohichni paraleli u zhinok z patolohiieiu endometriiu. Naukovo-praktychnyi zhurnal «Imunolohiia ta alerholohiia» 4:17.

2. Benyuk VA, Scherba EA, Lastovetskaya LD, Boychuk YuI, Onischuk NS. Sovremennyiy menedzhment bakterialnogo vaginoza u zhenschin reproduktivnogo vozrasta. The International Scientific Association «Science & Genesis» European Scientific Project. Scientific and educational journal:7.

3. Beniuk VO, Shcherba OA. 2013. Osoblyvosti funktsionalnoho stanu slyzovoi obolonky pikhvy ta shyiky matky za umov mikst-infektsii. Zdorove zhenshchiny 3:71–76.

4. Hryshchenko VI. 2000. Khlamidiina infektsiia u hinekolohichnykh khvorykh z neplidnistiu. Pediatriia, akusherstvo ta hinekolohiia 3:41–43.

5. Romaschenko OV, Voziyanova SV, Rudenko AV, Yakovenko LF. 2016. Lechenie vospalitelnyih zabolevaniy organov malogo taza, obuslovlennyih mikst-infektsiey. Zdorove zhenschiny 6:134–143.

6. Lee YK, Mazmanian SK. 2010. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 330:1768–1773. https://doi.org/10.1126/science.1195568; PMid:21205662 PMCid:PMC3159383

7. Qin J, Li R, Raes J, Arumugam M et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. MetaHIT Consortium. Nature. 464(7285):59–65. https://doi.org/10.1038/nature08821; PMid:20203603 PMCid:PMC3779803

8. Sjogren YM, Tomicic S, Lundberg A et al. 2009. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin. Exp. Allergy. 39(12):1842–1851. https://doi.org/10.1111/j.1365-2222.2009.03326.x; PMid:19735274

9. Ichinohe T, Pang IK, Kumamoto Y et al. 2011. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. U S A. 108(13):5354–5359. https://doi.org/10.1073/pnas.1019378108; PMid:21402903 PMCid:PMC3069176

10. Fitzgerald KA. 2010. NLR–containing inflammasomes: Central mediators of host defense and inflammation. European Journal of Immunology 40(3):595–598. https://doi.org/10.1002/eji.201040331; PMid:20201007

11. Coulombe F, Fiola S, Akira S, Cormier Y, Gosselin J. 2012. Muramyl dipeptide induces NOD2–dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection. PLoS One. 7(5):e36734. https://doi.org/10.1371/journal.pone.0036734; PMid:22590599 PMCid:PMC3348889

12. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. 2009. Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. 15(2):300–310. https://doi.org/10.1002/ibd.20602; PMid:18626975

13. De Vrese M, Schrezenmeir J. 2008. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111:1–66. https://doi.org/10.1007/10_2008_097; PMid:18461293

14. Johansson MA, Sjogren YM, Persson JO et al. 2011. Early colonization with a group of Lactobacilli decreases the risk for allergy at five years of age despite allergic heredity. PLoS One. 6(8):e23031. https://doi.org/10.1371/journal.pone.0023031; PMid:21829685 PMCid:PMC3148229

15. Marschan E, Kuitunen M, Kukkonen K et al. 2008. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low–grade inflammation. Clinical & Experimental Allergy. 38(4):611–618. https://doi.org/10.1111/j.1365-2222.2008.02942.x; PMid:18266878

16. Lopez P, Gonzalez–Rodriguez I, Gueimonde M, Margolles A, Suarez A. 2011. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS One. 6(9):e24776. doi: 10. 1371/ journal. pone.0024776.

17. Dong H, Rowland I, Yaqoob P. 2012. Comparative effects of six probiotic strains on immune function in vitro. Br. J. Nutr. 108(3):459–470. https://doi.org/10.1017/S0007114511005824; PMid:22054064

18. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. 2015. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. Front Microbiol. 6:1528. PMid:26834706

19. Ronald F Lamont, Jack D Sobel, Robert A Akins, Sonia S Hassan, Chaiworapongsa T, Kusanovic JP, Romero R. 2011, Apr. The vaginal microbiome: New information about genital tract flora using molecular based techniques. BJOG. 118(5):533–549. https://doi.org/10.1111/j.1471-0528.2010.02840.x; PMid:21251190 PMCid:PMC3055920

20. Shipitsyna E, Roos A, Datcu R, Hallйn A, Fredlund H, Jensen JS, Engstrand L, Unemo M. 2013, Apr 9. Composition of the vaginal microbiota in women of reproductive age—sensitive and specific molecular diagnosis of bacterial vaginosis is possible? PLoS One. 8(4):e60670. https://doi.org/10.1371/journal.pone.0060670; PMid:23585843 PMCid:PMC3621988

21. Woodman Z. 2016. Can one size fit all? Approach to bacterial vaginosis in sub-Saharan Africa. Ann Clin Microbiol Antimicrob. 15:16. https://doi.org/10.1186/s12941-016-0132-6; PMid:26968525 PMCid:PMC4787044

22. Aldunate M, Srbinovski D, Hearps AC, Latham CF, Ramsland PA, Gugasyan R, Cone RA, Tachedjian G. 2015. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol. 6:164. https://doi.org/10.3389/fphys.2015.00164; PMid:26082720 PMCid:PMC4451362

23. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. 2011, Nov 9. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. (11):CD004827. https://doi.org/10.1002/14651858.cd004827.pub3